<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0120-2448</journal-id>
<journal-title><![CDATA[Acta Medica Colombiana]]></journal-title>
<abbrev-journal-title><![CDATA[Acta Med Colomb]]></abbrev-journal-title>
<issn>0120-2448</issn>
<publisher>
<publisher-name><![CDATA[Asociacion Colombiana de Medicina Interna]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0120-24482016000300181</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Tratamiento hipolipemiante y su efectividad en pacientes de cuatro ciudades colombianas]]></article-title>
<article-title xml:lang="en"><![CDATA[Lipid-lowering therapy and its effectiveness in patients from four Colombian cities]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Machado-Alba]]></surname>
<given-names><![CDATA[Jorge Enrique]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Machado-Duque]]></surname>
<given-names><![CDATA[Manuel Enrique]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Yepes]]></surname>
<given-names><![CDATA[María Camila]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Manrique]]></surname>
<given-names><![CDATA[Santiago]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Tobón]]></surname>
<given-names><![CDATA[Luisa Marcela]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Tecnológica de Pereira  ]]></institution>
<addr-line><![CDATA[Pereira Risaralda]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad Tecnológica de Pereira  ]]></institution>
<addr-line><![CDATA[Pereira Risaralda]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad Tecnológica de Pereira  ]]></institution>
<addr-line><![CDATA[Pereira Risaralda]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>09</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>09</month>
<year>2016</year>
</pub-date>
<volume>41</volume>
<numero>3</numero>
<fpage>181</fpage>
<lpage>186</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0120-24482016000300181&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0120-24482016000300181&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0120-24482016000300181&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción: la prevalencia de enfermedad cardiovascular ha aumentado, la hipercolesterolemia se ha asociado como factor de riesgo y se desconoce en algunas poblaciones cuántos pacientes logran el control metabólico.  Objetivo: determinar la efectividad del tratamiento hipolipemiante en pacientes afiliados al sistema de salud colombiano.  Métodos: estudio de corte transversal para determinar la efectividad del tratamiento hipolipemiante en una muestra aleatoria de 211 pacientes adultos tratados con estatinas, en cuatro ciudades colombianas entre 2012 y 2013. Se obtuvieron variables sociodemográficas, antropométricas, cardiovasculares, farmacológicas y paraclínicas (Colesterol Total (CT), LDL, HDL, triglicéridos).  Resultados: se encontró predominio femenino (56,4%), promedio de edad 64±12 años, tratados en monoterapia con atorvastatina 78.6% y lovastatina 19.9%. El 43.4% de los casos de alto riesgo alcanzó la meta de C-LDL. El promedio de colesterol-LDL inicial en pacientes con atorvastatina fue de 103.7±48.2 mg/dL y final fue 81.9±31.2 mg/dL con una reducción promedio de 21.0% de los valores, esta diferencia fue estadísticamente significativa (p&lt;0.001). Ser tratado en la ciudad de Manizales (OR: 2.44; IC95%: 1.029-5.789; p=0.043) y tener historia personal de infarto agudo de miocardio (OR:2.96; IC95%: 1.256-6.980; p=0.013) se asociaron con aumento de la probabilidad de controlar la dislipidemia, mientras que ser tratado con lovastatina (OR:0.03; IC95%: 0.855-4.614; p=0.02) se asoció con disminución en la probabilidad de lograr el control.  Discusión: el tratamiento hipolipemiante fue realizado principalmente con atorvastatina seguido por una baja proporción de lovastatina; sin embargo, los pacientes de alto riesgo cardiovascular tratados con este último tuvieron menor probabilidad de llegar al control metabólico. (Acta Med Colomb 2016; 41: 181-186).]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction: The prevalence of cardiovascular disease has increased; hypercholesterolemia has been associated as a risk factor and the number of patients achieving metabolic control in some populations is unknown.  Objective: To determine the effectiveness of lipid-lowering therapy in patients affiliated to the Colombian Health System.  Methods: A cross-sectional study to determine the effectiveness of lipid-lowering therapy in a random sample of 211 adult patients treated with statins in four Colombian cities between 2012 and 2013. Sociodemographic, anthropometric, cardiovascular, pharmacological and paraclinical variables were obtained (total cholesterol (CT), LDL, HDL, triglycerides).  Results: There was female predominance (56.4%), mean age 64 ± 12 years, 78.6% were treated with atorvastatin monotherapy and 19.9% with lovastatin. 43.4% of high-risk cases reached the target of C-LDL. The average initial LDL cholesterol in patients with atorvastatin was 103.7 ± 48.2 mg / dL and the final was 81.9 ± 31.2 mg / dL with an average reduction of 21.0% of the values. This difference was statistically significant (p &lt;0.001). Being treated in the city of Manizales (OR: 2.44; 95% CI: 1029-5789; p = 0.043) and having personal history of acute myocardial infarction (OR: 2.96; 95% CI: 1256-6980; p = 0.013) were associated with increased likelihood of controlling dyslipidemia while being treated with lovastatin (OR: 0.03; 95% CI: 0855-4614; p = 0.02) was associated with decreased likelihood of achieving control.  Discussion: lipid-lowering therapy was performed mainly with atorvastatin followed by a low proportion of lovastatin; however patients at high cardiovascular risk treated with the latter were less likely to get metabolic control. (Acta Med Colomb 2016; 41: 181-186).]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[dislipidemia]]></kwd>
<kwd lng="es"><![CDATA[efectividad]]></kwd>
<kwd lng="es"><![CDATA[inhibidores de hidroximetilglutaril-coa reductasas]]></kwd>
<kwd lng="es"><![CDATA[resultado del tratamiento]]></kwd>
<kwd lng="es"><![CDATA[enfermedades cardiovasculares]]></kwd>
<kwd lng="es"><![CDATA[farmacoepidemiología]]></kwd>
<kwd lng="en"><![CDATA[dyslipidemia]]></kwd>
<kwd lng="en"><![CDATA[effectiveness]]></kwd>
<kwd lng="en"><![CDATA[hydroxymethylglutaryl-CoA reductase inhibitors]]></kwd>
<kwd lng="en"><![CDATA[treatment outcome]]></kwd>
<kwd lng="en"><![CDATA[cardiovascular diseases]]></kwd>
<kwd lng="en"><![CDATA[pharmacoepidemiology]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<collab>Instituto Nacional de Salud, Colombia</collab>
<source><![CDATA[Boletín No. 1]]></source>
<year>2013</year>
<publisher-name><![CDATA[Observatorio Nacional de Salud]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="">
<collab>World Health Organization (WHO)</collab>
<source><![CDATA[Cardiovascular diseases, deaths per 100 000 Data by country]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Patiño-Villada]]></surname>
<given-names><![CDATA[FA]]></given-names>
</name>
<name>
<surname><![CDATA[Arango-Vélez]]></surname>
<given-names><![CDATA[EF]]></given-names>
</name>
<name>
<surname><![CDATA[Quintero-Velásquez]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Arenas-Sosa]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiovascular risk factors in an urban Colombia population]]></article-title>
<source><![CDATA[Rev Salud Publica (Bogota)]]></source>
<year>2011</year>
<volume>13</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>433-45</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Machado-Alba]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Machado-Duque]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiovascular risk factors prevalence among patients with dyslipidemia in Colombia]]></article-title>
<source><![CDATA[Rev Peru Med Exp Salud Publica]]></source>
<year>2013</year>
<volume>30</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>205-11</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Genest]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Frohlich]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Fodor]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[McPherson]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Working Group on Hypercholesterolemia and Other Dyslipidemias Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update]]></article-title>
<source><![CDATA[CMAJ]]></source>
<year>2003</year>
<volume>169</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>921-4</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stone]]></surname>
<given-names><![CDATA[NJ]]></given-names>
</name>
<name>
<surname><![CDATA[Robinson]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[Lichtenstein]]></surname>
<given-names><![CDATA[AH]]></given-names>
</name>
<name>
<surname><![CDATA[Bairey Merz]]></surname>
<given-names><![CDATA[CN]]></given-names>
</name>
<name>
<surname><![CDATA[Blum]]></surname>
<given-names><![CDATA[CB]]></given-names>
</name>
<name>
<surname><![CDATA[Eckel]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[American College of Cardiology/American Heart Association Task Force on Practice Guidelines 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2014</year>
<volume>63</volume>
<numero>25</numero>
<issue>25</issue>
<page-range>2889-934</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Reiner]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Catapano]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[De Backer]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Graham]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Taskinen]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Wiklund]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical Practice Guidelines Committee of the Spanish Society of Cardiology [ESC/EAS Guidelines for the management of dyslipidaemias]]></article-title>
<source><![CDATA[Rev Esp Cardiol]]></source>
<year>2011</year>
<volume>64</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1168</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Machado-Alba]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Murillo-Muñoz]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Machado-Duque]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effectiveness of lipid-lowering therapy among a sample of patients in Colombia]]></article-title>
<source><![CDATA[Rev Panam Salud Pública]]></source>
<year>2013</year>
<volume>33</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>383-90</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="">
<collab>Ministerio de Salud y Protección Social</collab>
<source><![CDATA[Comisión de regulación en salud CRES. Acuerdo 029 de 2011]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lynch]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
<name>
<surname><![CDATA[Cooke]]></surname>
<given-names><![CDATA[CE]]></given-names>
</name>
<name>
<surname><![CDATA[Rosen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Gandhi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Bullano]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Managing dyslipidemia in primary care with restricted access to lipid-modifying therapy]]></article-title>
<source><![CDATA[Am Health Drug Benefits]]></source>
<year>2010</year>
<volume>3</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>340-9</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bozentowicz-Wikarek]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kocetak]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Smertka]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Olszanecka-Glinianowicz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Chudek]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effectiveness of lipid-lowering therapy with statins for secondary prevention of atherosclerosis--guidelines vs reality]]></article-title>
<source><![CDATA[Pharmacol Rep]]></source>
<year>2012</year>
<volume>64</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>377-85</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lurán]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[López]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Pinilla]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Situación de la mortalidad por enfermedades cardiovasculares en seis regiones de Colombia, 1996-2005]]></article-title>
<source><![CDATA[Inf Quinc Epidemiol Nac]]></source>
<year>2008</year>
<volume>13</volume>
<numero>13</numero>
<issue>13</issue>
<page-range>177-203</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Meyer]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
<name>
<surname><![CDATA[Schultz]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[O&#8217;Donnell]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Sasane]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Patterns and effectiveness of lipid-lowering therapies in a managed care environment]]></article-title>
<source><![CDATA[Value Health]]></source>
<year>2005</year>
<volume>8</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>601-12</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nissen]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Tuzcu]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Schoenhagen]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[BG]]></given-names>
</name>
<name>
<surname><![CDATA[Ganz]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Vogel]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[REVERSAL Investigators Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2004</year>
<volume>291</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1071-80</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fulcher]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[O&#8217;Connell]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Voysey]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Emberson]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Blackwell]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Mihaylova]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<collab>Cholesterol Treatment Trialists&#8217; Collaboration</collab>
<article-title xml:lang=""><![CDATA[Efficacy and safety of LDL-lowering therapy among men and women meta-analysis of individual data from 174,000 participants in 27 randomised trials]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2015</year>
<volume>385</volume>
<numero>9976</numero>
<issue>9976</issue>
<page-range>1397-405</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alnouri]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Wood]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Kotseva]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Ibrahim]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Which statin worked best to achieve lipid level targets in a European registry A post-hoc analysis of the EUROASPIRE III for coronary heart disease patients]]></article-title>
<source><![CDATA[J Saudi Heart Assoc]]></source>
<year>2014</year>
<volume>26</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>183-91</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ankam]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Feldman]]></surname>
<given-names><![CDATA[DI]]></given-names>
</name>
<name>
<surname><![CDATA[Blaha]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Martin]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Improving lipid control following myocardial infarction]]></article-title>
<source><![CDATA[Curr Opin Cardiol]]></source>
<year>2014</year>
<volume>29</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>454-66</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pursnani]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Massaro]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[D&#8217;Agostino Sr]]></surname>
<given-names><![CDATA[RB]]></given-names>
</name>
<name>
<surname><![CDATA[O&#8217;Donnell]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Hoffmann]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guideline-Based Statin Eligibility, Coronary Artery Calcification, and Cardiovascular Events]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2015</year>
<volume>314</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>134-41</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
